# NRG-GU008 (apalutamide): what clinicians are saying

> 304 statements from 30 sources (9 videos, 20 posts, 1 registry record), 236 of them from 42 confirmed clinicians, each linked to its source. Commentary checked Nov 15, 2026.

## Report

- Trial: Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
- NCT ID: NCT04134260
- Registry: https://clinicaltrials.gov/study/NCT04134260
- Sponsor: NRG Oncology
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: apalutamide
- Indication: node-positive prostate cancer after radical prostatectomy
- Version: v1.0.0, edition 1
- Accepted: 2026-11-15 UTC
- Last checked: 2026-11-15 UTC
- Release hash: df47c56de794af406b0f820858d846acf1688a069b15348a311111a9339888f8

## Counts

- Commentary sources screened: 61
- Sources cited by verified statements: 30
- Verified statements: 304
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 236
- Findings: 12
- Named people in screened sources (unnamed speakers and accounts not counted): 59
- Speakers cited: 58
- Cited speakers with a verified identity: 54
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 42
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 42
- By role and specialty (the abstract's specialty counts):
  - 20 physician, Radiation oncology
  - 9 physician, specialty not confirmed
  - 6 physician, Surgical oncology
  - 4 physician, Medical oncology
  - 3 physician, Urology
- Organisational or shared accounts (not counted as people): 3

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Radiation oncologists see NRG-GU008 as a way to close an evidence gap, not a basis for routine ARPI use; one highlights Formula 509’s inconclusive findings. Duration draws differing interpretations: one radiation oncologist tentatively favors shorter ADT because of possible other-cause mortality, whereas another draws on RADICALS-HD to explain the rationale for longer ADT. The mortality concern is not a trial finding; the sources reviewed for this edition describe no benefit or comparative-safety results from the trial.

## Question clinicians left open

What do clinicians say they need to see from INNOVATE on metastasis-free survival, quality of life and short- and long-term toxicity before routinely adding apalutamide to salvage radiation and hormone therapy for pathologically node-positive prostate cancer with detectable PSA after prostatectomy?

From finding F1 (19 statements from 4 speakers in 5 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Speakers look to INNOVATE to answer whether node-positive salvage treatment benefits from ARPI intensification
  - 19 statements from 4 speakers in 5 sources, 2 of them podcasts or videos.
  - 4 of the report's 42 cited clinicians.
- F2. One speaker questions whether INNOVATE's two-year hormonal course is too long
  - 11 statements from 3 speakers in 3 sources, all podcasts or videos.
  - 3 of the report's 42 cited clinicians.
- F3. X accounts distinguish detectable-PSA salvage eligibility from the adjuvant-treatment debate
  - 9 statements from 6 speakers in 5 sources, 2 of them podcasts or videos.
  - 6 of the report's 42 cited clinicians.
- F4. X accounts challenge the original dual-agent rationale; one trial-linked account explains reconsideration
  - 10 statements from 6 speakers in 5 sources.
  - 4 of the report's 42 cited clinicians.
- F5. X accounts weigh radiotherapy flexibility against postoperative tolerability uncertainty
  - 11 statements from 3 speakers in 2 sources.
  - 3 of the report's 42 cited clinicians.
- F6. Speakers see participation as dependent on practical access and referral support
  - 22 statements from 5 speakers in 14 sources, 5 of them podcasts or videos.
  - 5 of the report's 42 cited clinicians.
- F10. X accounts differ on adding an ARSI for PET-detected pelvic nodal persistence or relapse
  - 14 statements from 8 speakers in 1 source.
  - 5 of the report's 42 cited clinicians.

### Beyond the trial population

- F7. Speakers disagree on adjuvant treatment versus selective early salvage for postoperative pN1 disease
  - 40 statements from 20 speakers in 4 sources, 1 of them a podcast or video.
  - 14 of the report's 42 cited clinicians.
- F8. X accounts dispute whether systemic benefit makes pelvic radiation unnecessary
  - 13 statements from 3 speakers in 1 source.
  - 2 of the report's 42 cited clinicians.
- F9. X accounts question whether PSMA-directed focal treatment can substitute for early salvage fields
  - 25 statements from 15 speakers in 7 sources, 3 of them podcasts or videos.
  - 12 of the report's 42 cited clinicians.
- F11. Speakers argue for risk-guided hormone use rather than uniform postoperative intensification
  - 48 statements from 5 speakers in 5 sources, 4 of them podcasts or videos.
  - 5 of the report's 42 cited clinicians.
- F12. One X account proposes ctDNA-adapted escalation and de-escalation, while another questions the comparison with PSA
  - 4 statements from 1 speaker in 1 source.
  - 1 of the report's 42 cited clinicians.

5 of the 12 findings and 124 of the 304 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 19 | 9 | 5 | 4 | 3 |
| F2 | 11 | 9 | 3 | 3 | 2 |
| F3 | 9 | 9 | 5 | 6 | 3 |
| F4 | 10 | 10 | 5 | 6 | 3 |
| F5 | 11 | 12 | 2 | 3 | 3 |
| F6 | 22 | 20 | 14 | 5 | 3 |
| F10 | 14 | 13 | 1 | 8 | 3 |
| F7 | 40 | 35 | 4 | 20 | 3 |
| F8 | 13 | 14 | 1 | 3 | 3 |
| F9 | 25 | 26 | 7 | 15 | 3 |
| F11 | 48 | 34 | 5 | 5 | 3 |
| F12 | 4 | 4 | 1 | 1 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 8 | 3 | 1 | 0 | 7 | 21 | 9 | 2 posts and articles, 2 podcasts and video, 1 registry |
| F2 | 3 | 3 | 1 | 2 | 2 | 13 | 0 | 3 podcasts and video |
| F3 | 3 | 2 | 0 | 1 | 3 | 9 | 0 | 2 posts and articles, 2 podcasts and video, 1 registry |
| F4 | 6 | 2 | 0 | 0 | 2 | 10 | 0 | 5 posts and articles |
| F5 | 1 | 2 | 3 | 0 | 5 | 11 | 1 | 2 posts and articles |
| F6 | 13 | 0 | 3 | 0 | 6 | 22 | 3 | 9 posts and articles, 5 podcasts and video |
| F10 | 12 | 0 | 1 | 0 | 1 | 14 | 5 | 1 post or article |
| F7 | 29 | 3 | 5 | 1 | 2 | 45 | 4 | 3 posts and articles, 1 podcast or video |
| F8 | 8 | 3 | 1 | 0 | 1 | 14 | 1 | 1 post or article |
| F9 | 9 | 8 | 1 | 2 | 5 | 25 | 3 | 4 posts and articles, 3 podcasts and video |
| F11 | 39 | 5 | 1 | 1 | 2 | 62 | 4 | 1 post or article, 4 podcasts and video |
| F12 | 3 | 1 | 0 | 0 | 0 | 4 | 0 | 1 post or article |

### Trial dimensions

- Primary endpoint: Metastasis-free survival (MFS): F1 (4 shared claims), F2 (1 shared claims)
- Secondary endpoints: F1 (1 shared claims)
- Population and setting: F1 (1 shared claims), F2 (2 shared claims), F3 (8 shared claims), F4 (1 shared claims), F6 (2 shared claims)
- The comparison: F1 (2 shared claims), F2 (4 shared claims), F3 (3 shared claims), F4 (7 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (1 shared claims), F5 (3 shared claims)
- Design and conduct: F1 (1 shared claims), F3 (1 shared claims), F4 (3 shared claims), F6 (12 shared claims)

## Abbreviations

- ADT: androgen deprivation therapy
- ARPI: androgen receptor pathway inhibitor
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- PET: positron emission tomography
- PSA: prostate-specific antigen
- PSMA: prostate-specific membrane antigen

## Examples from the report

Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.

- Radiation oncologist, US, identity checked against NPI · video · Feb 2024 (finding F1): A radiation oncologist encourages enrollment in NRG GU 008 INNOVATE wherever the study is open and awaits its results.
- Radiation oncologist, US, identity checked against NPI · video · May 2024 (finding F3): A radiation oncologist asks whether standard hormone therapy should be intensified with an ARPI in the adjuvant setting, identifies INNOVATE as investigating apalutamide added to radiation and hormone therapy, and believes this needs more trial work.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 14 sections | Paid |
| Verified statements with short source quotes and links | 304 | Paid |
| Who said each statement: the cited speakers | 58 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 42 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 54 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 15 | Free |
| Sources with links | 30 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 42 of the 58 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

15 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Metastasis-free survival (MFS) | discussed | 6 | 2 |
| Secondary endpoints | discussed | 8 | 5 |
| Population and setting | discussed | 14 | 9 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 17 | 9 |
| Safety and tolerability | discussed | 14 | 6 |
| Design and conduct | discussed | 16 | 10 |
| Adjuvant versus early-salvage timing and control-arm interpretation | discussed | 42 | 4 |
| Systemic addition versus replacement of local treatment | discussed | 18 | 2 |
| Advanced imaging, stage migration and limits of negative scans | discussed | 21 | 8 |
| Radiation fields, fractionation, focal substitution and boosts | discussed | 34 | 5 |
| Patient selection, genomic risk and postoperative work-up | discussed | 38 | 7 |
| Alternative regimens for PET-detected pelvic nodal persistence or relapse | discussed | 14 | 1 |
| Enrollment access, imaging costs, referrals and patient information | discussed | 26 | 17 |
| Duration, evidence transfer and clinically meaningful benefit | discussed | 41 | 6 |
| Proposed ctDNA-adapted escalation and de-escalation research | discussed | 4 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 128 statements · 42%** | | | |
| YouTube | 128 | 9 | 11 |
| Podcasts | 0 | 0 | 2 |
| **Posts · 175 statements · 58%** | | | |
| X threads | 175 | 20 | 47 |
| Bluesky threads | 0 | 0 | 1 |
| **Primary sources · 1 statement · 0%** (cited for context, not screened) | | | |
| Registry (primary source, cited for context) | 1 | 1 | not screened |

- Screened window: 2019-11-09 to 2026-10-21
- Cited window: 2020-10-16 to 2026-10-21
- Retrieved: 2026-11-15

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
- Registry: NCT04134260 (https://clinicaltrials.gov/study/NCT04134260)
- Study IDs: NRG-GU008 · NCI-2019-06838 (CTRP (Clinical Trial Reporting Program)) · U10CA180868
- Sponsor: NRG Oncology
- Collaborators: National Cancer Institute (NCI)
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 586 (estimated)
- Start: 2020-04-16 (actual)
- Primary completion: 2026-11-01 (estimated)
- Primary endpoint: Metastasis-free survival (MFS) (From randomization to detection of metastatic disease or death from any cause, assessed up to 7.5 years)
- Intervention: Apalutamide (drug)
- Intervention: Biospecimen Collection (procedure)
- Intervention: Bone Scan (procedure)
- Intervention: Computed Tomography (procedure)
- Intervention: Hormone Therapy (drug)
- Intervention: Magnetic Resonance Imaging (procedure)
- Intervention: Positron Emission Tomography (procedure)
- Intervention: Quality-of-Life Assessment (other)
- Intervention: Questionnaire Administration (other)
- Intervention: Radiation Therapy (radiation)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a view on tailoring salvage treatment because not every patient needs intensification; a view on clinically actionable recurrence and the factors guiding salvage-treatment decisions; a view on variation in imaging work-up and treatment initiation for recurrence after prostatectomy and radiotherapy; a question about avoiding unnecessary therapy and selecting treatment intensity as advanced imaging changes staging; a view on distinguishing recurrence from actionable progression when assessing clinically meaningful salvage-treatment outcomes; a question about imaging-positive disease prevalence among patients considered for salvage radiotherapy.
- 1 more clinician view in the sources used in this report is not yet captured as evidence in this edition.
- 135 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 38 sources about other trials or topics are not included; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.
- The sources reviewed for this edition are not a representative sample of HCP opinion; no prevalence, consensus proportion or independent-clinician count can be inferred.
- Discussion that did not use the searched trial names or identifiers may be missing. Coverage of unnamed references and transcription variants is therefore incomplete.
- Some media passages cannot be confidently assigned to a named speaker. Their views remain attributed to the discussion or presentation rather than to a roster participant.
- Some comments qualifying salvage-radiotherapy toxicity and the distinction between biochemical recurrence and acting on recurrence are not fully represented, limiting completeness on those issues.
- No INNOVATE efficacy or comparative-safety readout is described. Other-study findings, personal experience, hypotheses and cure-rate aspirations are not results of INNOVATE.
- Full protocol and detailed amendment documentation were unavailable. Historical statements about drugs, radiation modalities, imaging and geographic participation should not be treated as current requirements.
- Recruitment messages span several years and include both a completion announcement and a later description of an ongoing study. They do not establish live enrollment status.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Several important arguments extrapolate from broader salvage, adjuvant, clinically node-positive or intact-prostate populations. Those boundaries limit application to INNOVATE's detectable-PSA postoperative pN-positive population.
- Reposts, repeated statements and excerpts from the same presentation do not provide additional independent support.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-15 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-15 UTC. No changes.

## Offer

- Size: Deep · 304 verified statements · 236 from 42 confirmed clinicians
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $3,400
- 6 months of updates: $4,900
- 12 months of updates: $6,800
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (54 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/nrg-gu008-nct04134260
- Agents: POST https://www.erudio.com/api/orders with {"report": "nrg-gu008-nct04134260", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=nrg-gu008-nct04134260

## Cite

Erudio Health. NRG-GU008 (NCT04134260): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 15, 2026. https://www.erudio.com/reports/nrg-gu008-nct04134260

## Questions

### How much does the NRG-GU008 report cost?

One edition costs $1,950 (Deep · 304 verified statements · 236 from 42 confirmed clinicians). With updates: 3 months $3,400, 6 months $4,900, 12 months $6,800. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the NRG-GU008 report cover?

304 statements from 30 sources (9 videos, 20 posts, 1 registry record), 236 of them from 42 confirmed clinicians, each linked to its source. Commentary checked Nov 15, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the NRG-GU008 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "nrg-gu008-nct04134260" }) previews it and create_order({ "report": "nrg-gu008-nct04134260", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the NRG-GU008 report?

Edition 1 (version 1.0.0), accepted Nov 15, 2026 UTC; last checked for new commentary Nov 15, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/nrg-gu008-nct04134260.json
- Markdown: https://www.erudio.com/reports/nrg-gu008-nct04134260.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/nrg-gu008-nct04134260/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "nrg-gu008-nct04134260"}`
